Chloroquine/lopinavir/ritonavir/umifenovirQTc interval prolongation, drug interaction and off-label use: 2 case reports

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2020年 / 1817卷 / 1期

关键词：

D O I：

10.1007/s40278-020-82071-8

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：112 / 112

相关论文

共 50 条

[1] Lopinavir/ritonavir/tocilizumabHypertriglyceridaemia following off-label use: 2 case reports
Reactions Weekly, 2020, 1824 (1) : 180 - 180
[2] Chloroquine/lopinavir/ritonavirDrug (lopinavir) plasma concentration increased following drug interaction and off-label use: 11 case reports
Reactions Weekly, 2023, 1957 (1) : 141 - 141
[3] LacosamidePR interval prolongation and off-label use: 2 case reports
Reactions Weekly, 2019, 1735 (1) : 166 - 166
[4] Lopinavir/ritonavirIncreased liver enzymes level, QT interval prolongation and off-label use: 9 case reports
Reactions Weekly, 2023, 1940 (1) : 245 - 245
[5] Hydroxychloroquine/lopinavir/ritonavirVomiting and QTc-interval prolongation following off-label therapy: 2 case reports
Reactions Weekly, 2021, 1858 (1) : 186 - 186
[6] Hydroxychloroquine/lopinavir/ritonavir/peginterferonDiarrhoea and off-label treatment: 4 case reports
Reactions Weekly, 2022, 1907 (1) : 241 - 241
[7] Multiple drugsQTc interval prolongation following off-label use: 5 case reports
Reactions Weekly, 2023, 1964 (1) : 316 - 316
[8] Multiple drugsQTc interval prolongation following off-label use: 5 case reports
Reactions Weekly, 2022, 1908 (1) : 408 - 408
[9] Lopinavir/ritonavirLack of efficacy following off-label use: 2 case reports
Reactions Weekly, 2022, 1903 (1) : 225 - 225
[10] Lopinavir/ritonavir/sirolimus interactionHepatitis following an off-label use: case report
Reactions Weekly, 2022, 1908 (1) : 328 - 328

← 1 2 3 4 5 →